Clinical Trials

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
April 18, 2018With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
April 17, 2018This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
April 06, 2018In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
January 22, 2018Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
January 19, 2018Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.

Bridging the Gap in Genetic Cancer Research Data on Minority Populations
January 01, 2018Investigators sought to determine why so few biospecimens were available for research from minority populations of women with breast cancer.

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer
December 08, 2017Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.

Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
October 20, 2017PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.

Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
October 19, 2017Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.

New Class of Clinical Trial Enhances Research on Cancer Care Delivery
October 17, 2017What is a CCDR clinical trial and how does it differ from clinical trials that test new drugs?

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
October 16, 2017Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.

High Rates of Adverse Events Lead to Earlier Dropouts in Phase 1 Cancer Trials
October 10, 2017Phase 1 trials are used to determine the safety profiles of treatment regimens. In this retrospective review, investigators sought to understand the reasons participants in these studies drop out.

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma
August 25, 2017The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.

More Patients Enrolled in Cancer Trials Under ACA
July 26, 2017Insurer approval rates rose from 85 percent before Affordable Care Act to 95 percent after the health care bill was enacted.

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
June 28, 2017An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.

Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
June 28, 2017Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).

Clinical Trials May Benefit Oncology Patients
June 22, 2017Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms

Older Patients Under-Represented in Cancer Drug Clinical Trials
June 15, 2017Older adults are underrepresented in clinical trials of cancer drugs, according to study findings presented at the 2017 ASCO Annual Meeting.

Older Adults Under-Represented in Cancer Drug Clinical Trials
June 08, 2017Patients aged 80 years and older had a cancer incidence of 16% in 2013 yet made up only 4% of cancer drug clinical trial participants during 2005-2015.

Cognitive Computing Expedites Matching Patients to Clinical Trials
June 06, 2017IBM Watson for Clinical Trial Matching compares study enrollment criteria with patient data in electronic medical records.

IL-11 Plus Glucocorticoids Safe, Effective for ITP in Adults
May 25, 2017Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.

Durable Response Seen in Advanced HCC With Nivolumab
May 03, 2017New data presented at the International Liver Congress 2017 suggest that nivolumab may produce long-term benefits in sorafenib-experienced patients with advanced HCC.

Barriers in Routine Care Coverage for Cancer Clinical Trial Participants Still Exist
April 05, 2017Despite the ACA mandate on coverage for clinical trial participants, many facilities involved in cancer research still coping with insurance denials for participants.

CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
March 29, 2017Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.

Characteristics of Clinical Trials and Barriers to Patient Enrollment Identified
March 27, 2017Study identifies characteristics of clinical trials and barriers to patient accrual.

Women May Significantly Benefit from Entering OB/GYN Clinical Trials
March 01, 2017The researchers hope the results will lead to an increase in clinicians offering trials to their patients and an increase in women volunteering to participate in trials.

VBPWPs Can Compliment Patient Management in Clinical Trials
February 23, 2017Video Based Personal Webpages (VBPWP) Can Be Used as a Compliment to Clinical Trial Patient Management

Clinical Trial Enrollment of Adolescent and Young Adult Patients With Cancer: A Systematic Review of the Literature and Proposed Solutions
February 09, 2017[Clinical Oncology in Adolescents and Young Adults] This research evaluates methods that have been utilized in the clinical trial enrollment for adolescent and young adults with cancer.

Video Tool to Increase Breast Cancer Clinical Trial Participation Among Black Women
December 09, 2016A new tool may show promise for improving clinical trial participation among black women with breast cancer, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |